Roivant Launches Phase 2b/3 Brepocitinib Trial In Lichen Planopilaris As Batoclimab Fails Primary Endpoint In Phase 3 Thyroid Eye Disease Studies

Benzinga Newsdesk www.benzinga.com Neutral 77.0%